{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:54Z","timestamp":1792788114384,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union and the Global Health EDCTP3 Joint Undertaking","award":["101145740"],"award-info":[{"award-number":["101145740"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"crossref"}]},{"name":"State Secretariat for Education Research and Innovation (SERI) of the Swiss Confederation","id":[{"id":"https:\/\/ror.org\/00mt8k932","id-type":"ROR","asserted-by":"crossref"}]},{"name":"UK Research and Innovation (UKRI) through the Horizon Europe Guarantee","award":["10121054"],"award-info":[{"award-number":["10121054"]}],"id":[{"id":"https:\/\/ror.org\/001aqnf71","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In 2022, the World Health Organisation recommended artemether-lumefantrine as the first-line treatment for uncomplicated malaria in first-trimester pregnancy. However, emerging drug resistance and WHO\u2019s recommendation for treatment diversification necessitate research on alternative artemisinin-based combination therapies (ACTs). We conducted a Real-Time (RT) Delphi survey to establish stakeholder views on safety endpoints and non-inferiority margins for a randomised controlled trial evaluating ACTs in first-trimester pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An international RT Delphi study was conducted between September and October 2024, including clinical researchers, regulators, policymakers, ethicists, and healthcare practitioners. Stakeholders completed an online survey, rating the importance of composite endpoints and maternal and infant safety-related outcomes on a 5-point Likert scale. Outcomes were ranked, and acceptable non-inferiority safety margin were explored. Quantitative responses were summarised descriptively, and free-text comments were analysed thematically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 54 stakeholders invited, 30 responded (56%). Most (23\/30, 77%) agreed that a composite safety endpoint consisting of miscarriage, stillbirth, and major congenital anomalies was informative for evaluating ACT safety in the first trimester. Maternal outcomes rated as critical included maternal death (27\/30, 90%), severe maternal anaemia (23\/30, 77%), renal failure (20\/30, 67%), and maternal intensive care admission (19\/29, 66%). For infant outcomes, major congenital anomalies (28\/30, 94%), stillbirth (26\/30, 87%), and neonatal death (25\/30, 83%) were considered essential. Most respondents endorsed a non-inferiority margin of HR\u2009=\u20091.2 as a pragmatic balance between trial feasibility and acceptable uncertainty around safety. Qualitative analysis highlighted support for the composite endpoint to address competing risks. However, concerns were raised regarding the non-specificity of some outcomes, such as preterm birth and small-for-gestational-age, which may be influenced by factors unrelated to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides a framework for researchers to determine key safety outcomes and acceptable non-inferiority margins for malaria treatment trials in the first trimester. Incorporating stakeholder perspectives into trial design can support evidence-informed policy and facilitate the deployment of a wider range of antimalarial treatments considered safe in early pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-026-06045-1","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:53:01Z","timestamp":1784353981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining safety parameters for first-trimester malaria treatment trials: stakeholder views from Real-Time Delphi survey"],"prefix":"10.1186","volume":"25","author":[{"given":"Sandra","family":"Bivegete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hellen","family":"Barsosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"El Gaaloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassoum","family":"Kayentao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Worrall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiweka","family":"Kaszubska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocent","family":"Valea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiko","family":"ter Kuile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dellicour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"6045_CR1","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/S2214-109X(22)00431-4","volume":"11","author":"V Reddy","year":"2007","unstructured":"Reddy V, Weiss DJ, Rozier J, Ter Kuile FO, Dellicour S. Global estimates of the number of pregnancies at risk of malaria from 2007 to 2020: a demographic study. Lancet Glob Health. 2007;11:e40\u20137.","journal-title":"Lancet Glob Health"},{"key":"6045_CR2","volume-title":"World malaria report 2024: addressing inequity in the global malaria response","author":"WHO","year":"2024","unstructured":"WHO. World malaria report 2024: addressing inequity in the global malaria response. Geneva: World Health Organization; 2024."},{"key":"6045_CR3","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/S2214-109X(14)70256-6","volume":"2","author":"PG Walker","year":"2014","unstructured":"Walker PG, ter Kuile FO, Garske T, Menendez C, Ghani AC. Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study. Lancet Glob Health. 2014;2:e460-467.","journal-title":"Lancet Glob Health"},{"key":"6045_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/cid\/ciy1073","volume":"69","author":"M Accrombessi","year":"2019","unstructured":"Accrombessi M, Yovo E, Fievet N, Cottrell G, Agbota G, Gartner A, et al. Effects of malaria in the first trimester of pregnancy on poor maternal and birth outcomes in Benin. Clin Infect Dis. 2019;69:1385\u201393.","journal-title":"Clin Infect Dis"},{"key":"6045_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-319","volume":"11","author":"JB Griffin","year":"2012","unstructured":"Griffin JB, Lokomba V, Landis SH, Thorp JM Jr., Herring AH, Tshefu AK, et al. Plasmodium falciparum parasitaemia in the first half of pregnancy, uterine and umbilical artery blood flow, and foetal growth: a longitudinal Doppler ultrasound study. Malar J. 2012;11:319.","journal-title":"Malar J"},{"key":"6045_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/cid\/ciu848","volume":"60","author":"BT Huynh","year":"2015","unstructured":"Huynh BT, Cottrell G, Cot M, Briand V. Burden of malaria in early pregnancy: a neglected problem? Clin Infect Dis. 2015;60:598\u2013604.","journal-title":"Clin Infect Dis"},{"key":"6045_CR7","doi-asserted-by":"publisher","first-page":"e1101","DOI":"10.1016\/S2214-109X(17)30340-6","volume":"5","author":"KA Moore","year":"2017","unstructured":"Moore KA, Simpson JA, Scoullar MJL, McGready R, Fowkes FJI. Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1101\u201312.","journal-title":"Lancet Glob Health"},{"key":"6045_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0877-6","volume":"15","author":"KA Moore","year":"2017","unstructured":"Moore KA, Simpson JA, Wiladphaingern J, Min AM, Pimanpanarak M, Paw MK, et al. Influence of the number and timing of malaria episodes during pregnancy on prematurity and small-for-gestational-age in an area of low transmission. BMC Med. 2017;15:117.","journal-title":"BMC Med"},{"key":"6045_CR9","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S1473-3099(18)30066-5","volume":"18","author":"S Rogerson","year":"2018","unstructured":"Rogerson S, Desai M, Mayor A, Sicuri E, Taylor S, vanEijk A. Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem. Lancet Infect Dis. 2018;18:e107\u201318.","journal-title":"Lancet Infect Dis"},{"key":"6045_CR10","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/infdis\/jiy738","volume":"220","author":"SJ Rogerson","year":"2019","unstructured":"Rogerson SJ, Meshnick S. Malaria in pregnancy: late consequences of early infections. J Infect Dis. 2019;220:1396\u20138.","journal-title":"J Infect Dis"},{"key":"6045_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2352-4642(20)30099-7","volume":"4","author":"M Saito","year":"2020","unstructured":"Saito M, Briand V, Min AM, McGready R. Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs. Lancet Child Adolesc Health. 2020;4:761\u201374.","journal-title":"Lancet Child Adolesc Health"},{"key":"6045_CR12","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/infdis\/jix530","volume":"216","author":"C Schmiegelow","year":"2017","unstructured":"Schmiegelow C, Matondo S, Minja DTR, Resende M, Pehrson C, Nielsen BB, et al. Plasmodium falciparum infection early in pregnancy has profound consequences for fetal growth. J Infect Dis. 2017;216:1601\u201310.","journal-title":"J Infect Dis"},{"key":"6045_CR13","volume-title":"Safety of artemisinin and non-artemisinin antimalarials in the first trimester of pregnancy: review of evidence","author":"S. RJCRGRD","year":"2023","unstructured":"S. RJCRGRD. Safety of artemisinin and non-artemisinin antimalarials in the first trimester of pregnancy: review of evidence. Geneva: World Health Organization; 2023."},{"key":"6045_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0140-6736(22)01881-5","volume":"401","author":"M Saito","year":"2023","unstructured":"Saito M, McGready R, Tinto H, Rouamba T, Mosha D, Rulisa S, et al. Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis. Lancet. 2023;401:118\u201330.","journal-title":"Lancet"},{"key":"6045_CR15","volume-title":"WHO Guidelines for malaria, 25 November 2022","author":"WHO","year":"2022","unstructured":"WHO. WHO Guidelines for malaria, 25 November 2022. Geneva: WHO; 2022."},{"key":"6045_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. 2022;13:6353.","journal-title":"Nat Commun"},{"key":"6045_CR17","volume-title":"Strategy to respond to antimalarial drug resistance in Africa","author":"WHO","year":"2022","unstructured":"WHO. Strategy to respond to antimalarial drug resistance in Africa. Geneva: WHO; 2022."},{"key":"6045_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02002-8","volume":"19","author":"M Saito","year":"2021","unstructured":"Saito M, Carrara VI, Gilder ME, Min AM, Tun NW, Pimanpanarak M, et al. A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border. BMC Med. 2021;19:132.","journal-title":"BMC Med"},{"key":"6045_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/0269216317690685","volume":"31","author":"S Junger","year":"2017","unstructured":"Junger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on conducting and reporting Delphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31:684\u2013706.","journal-title":"Palliat Med"},{"key":"6045_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.techfore.2017.01.023","volume":"118","author":"SCK Aengenheyster","year":"2017","unstructured":"Aengenheyster SCK, Gerhold L, et al. Real-time Delphi in practice- a comparative analysis of existing software-based tools. Technol Forecast Soc Change. 2017;118:15\u201327.","journal-title":"Technol Forecast Soc Change"},{"key":"6045_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12884-021-03588-w","volume":"21","author":"D Herman","year":"2021","unstructured":"Herman D, Lor KY, Qadree A, Horn D, D\u2019Souza R. Composite adverse outcomes in obstetric studies: a systematic review. BMC Pregnancy Childbirth. 2021;21:107.","journal-title":"BMC Pregnancy Childbirth"},{"key":"6045_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40264-025-01521-0","volume":"48","author":"JL Richardson","year":"2025","unstructured":"Richardson JL, Moore A, Stellfeld M, Geissb\u00fchler Y, Winterfeld U, Favre G, et al. Delphi method consensus on statistical analysis and reporting recommendations for single-arm pregnancy medication safety studies investigating pregnancy, birth and neonatal health outcomes: a contribution from IMI-ConcePTION. Drug Saf. 2025;48:643\u201354.","journal-title":"Drug Saf"},{"key":"6045_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003775","volume":"5","author":"S Fernandes","year":"2025","unstructured":"Fernandes S, Briggs A, Hanson K. Co-developing a comprehensive disease policy model with stakeholders: the case of malaria during pregnancy. PLoS Glob Public Health. 2025;5:e0003775.","journal-title":"PLoS Glob Public Health"},{"key":"6045_CR24","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/0002-9378(76)90497-X","volume":"125","author":"M Perlman","year":"1976","unstructured":"Perlman M, Potashnik G, Wise S. Hydramnion and fetal renal anomalies. Am J Obstet Gynecol. 1976;125:966\u20138.","journal-title":"Am J Obstet Gynecol"},{"key":"6045_CR25","volume-title":"Multiple first-line therapies as part of the response to antimalarial drug resistance: an implementation guide","author":"WHO","year":"2024","unstructured":"WHO. Multiple first-line therapies as part of the response to antimalarial drug resistance: an implementation guide. Geneva: WHO; 2024."},{"key":"6045_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06911-8","volume":"23","author":"N Attard","year":"2022","unstructured":"Attard N, Totton N, Gillies K, Goulao B. How do we know a treatment is good enough? A survey of non-inferiority trials. Trials. 2022;23:1021.","journal-title":"Trials"},{"key":"6045_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jclinepi.2009.06.003","volume":"63","author":"SR Johnson","year":"2010","unstructured":"Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol. 2010;63:355\u201369.","journal-title":"J Clin Epidemiol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-06045-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-06045-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-06045-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:57:02Z","timestamp":1791982622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-06045-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6045"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-06045-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8610596\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Liverpool School of Tropical Medicine (LSTM) Research Ethics Committee (Reference number: 24-034). Electronic informed consent was obtained from each study participant after reading the Participant Information Sheet, which provided information on the survey objectives, process, and data management. Each participant had to provide electronic consent by ticking a box on the survey entry webpage prior to commencing the survey.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"365"}}